Last updated: September 1, 2026
Aspirin-dipyridamole, marketed in the United States as Aggrenox, is a secondary stroke-prevention product whose commercial profile shifted from branded specialty medicine to low-cost generic therapy. The combination remains clinically relevant for selected patients with prior ischemic stroke or transient ischemic attack, but its financial outlook is constrained by generic competition, inexpensive clopidogrel, broad aspirin use, and the absence of meaningful remaining exclusivity.
The product contains aspirin 25 mg and extended-release dipyridamole 200 mg in a capsule administered twice daily. FDA approved Aggrenox in 1999 for reducing the risk of stroke in patients who have experienced a previous ischemic stroke or transient ischemic attack [1]. U.S. generic versions entered after the core patent period, eliminating the principal source of branded pricing power.
What is aspirin-dipyridamole and how is it used?
Aspirin-dipyridamole combines two antiplatelet mechanisms:
- Aspirin irreversibly inhibits platelet cyclooxygenase and thromboxane A2 production.
- Dipyridamole increases platelet cyclic AMP and has vasodilatory and antiplatelet effects.
- The extended-release formulation maintains dipyridamole exposure over the dosing interval.
The FDA-approved indication is secondary prevention of ischemic stroke in adults with a history of transient ischemic attack or completed ischemic stroke caused by thrombosis.
Clinical positioning
The combination competes primarily with:
- Clopidogrel monotherapy.
- Aspirin monotherapy.
- Short-term aspirin plus clopidogrel after selected minor stroke or high-risk TIA.
- Other antithrombotic regimens used for patients with cardioembolic risk, although anticoagulants are not direct substitutes in every clinical setting.
The PRoFESS trial found aspirin plus extended-release dipyridamole broadly comparable with clopidogrel for recurrent stroke prevention. The combination was associated with more major hemorrhage and more intracranial bleeding, while headache and treatment discontinuation were also important tolerability issues [2].
The 2021 American Heart Association/American Stroke Association guideline continues to identify aspirin, clopidogrel, and aspirin plus extended-release dipyridamole as antiplatelet options for noncardioembolic ischemic stroke or TIA secondary prevention [3].
When did Aggrenox lose market exclusivity?
Aggrenox lost its principal U.S. exclusivity position during the mid-2010s as generic aspirin and extended-release dipyridamole products reached the market. The exact commercial erosion date varied by manufacturer, regulatory approval, launch timing, and any settlement or launch restrictions.
| Milestone |
Approximate timing |
Commercial effect |
| FDA approval of Aggrenox |
1999 |
Established the branded combination |
| Mature branded sales period |
2000s to early 2010s |
Brand captured combination-therapy pricing |
| Core patent expiry period |
Mid-2010s |
Reduced protection against generic entry |
| Generic approvals and launches |
Mid-2010s onward |
Initiated rapid price and share erosion |
| Mature generic market |
Late 2010s onward |
Product became primarily a low-margin multisource medicine |
The product’s commercial exclusivity ended through the combined effect of patent expiry and generic approval. FDA approval of a generic does not itself establish the precise commercial launch date, because litigation settlements, launch agreements, manufacturing readiness, and supply arrangements can delay entry.
What patents protected aspirin-dipyridamole?
The key U.S. patent estate covered the combination of aspirin with extended-release dipyridamole and related pharmaceutical compositions. The estate was more commercially important than the individual active ingredients because both aspirin and dipyridamole were long-established compounds with no meaningful molecule-level exclusivity remaining.
Patent protection profile
| Protection category |
Strategic value |
Current commercial significance |
| Aspirin composition patents |
Low |
Aspirin is an old, inexpensive generic active ingredient |
| Dipyridamole composition patents |
Low |
Dipyridamole has long been off patent |
| Combined formulation patents |
High during the branded period |
Protected the commercial extended-release combination |
| Extended-release delivery claims |
High during the branded period |
Created the principal barrier to generic substitution |
| Method-of-use claims |
Moderate |
Supported secondary stroke-prevention positioning |
| Manufacturing and process claims |
Moderate to low |
Could raise technical barriers but rarely preserve premium pricing alone |
Published patent records associated with Aggrenox include patents directed to aspirin and dipyridamole pharmaceutical compositions and controlled-release formulations. The relevant patents have expired or reached the end of their practical enforcement period in the United States. Current generic competition confirms that the historical formulation estate no longer blocks FDA-approved substitution.
What is the Orange Book status of Aggrenox?
The FDA Orange Book is the principal U.S. source for approved products, therapeutic equivalence information, and listed patents. Aggrenox’s historical Orange Book profile reflected a branded prescription combination product with formulation-related patent protection. The commercial importance of those listings declined after patent expiry and the approval of therapeutically equivalent generic products [4].
The current market analysis should distinguish among:
- The original Aggrenox reference product.
- Authorized or branded-generic versions.
- ANDA-approved aspirin and extended-release dipyridamole capsules.
- Products with therapeutic-equivalence codes that permit pharmacy substitution under state law.
The Orange Book does not guarantee that every generic is available from every wholesaler. It identifies FDA approval and equivalence status, while actual market share depends on contracting, inventory, reimbursement, and pharmacy substitution.
Which companies challenged Aggrenox exclusivity?
Generic manufacturers challenged the branded product through abbreviated new drug applications. The commercial field has included large generic suppliers and contract manufacturers, with availability changing over time as companies enter, exit, or experience supply interruptions.
Potentially relevant market participants include:
- Teva Pharmaceuticals.
- Actavis, later part of Allergan and subsequently AbbVie.
- Mylan, later part of Viatris.
- Dr. Reddy’s Laboratories.
- Other ANDA holders and private-label suppliers.
The presence of multiple approved generic suppliers is more important than the identity of any single challenger. It creates price competition and limits the reference product’s ability to retain a material premium.
What Paragraph IV challenges affected Aggrenox?
A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed. Such certifications can trigger Hatch-Waxman litigation and a potential 30-month stay of ANDA approval.
Aggrenox’s major exclusivity period was contested through the normal generic challenge pathway, but the product no longer presents a meaningful current Paragraph IV barrier. The relevant commercial question is not whether a historical challenge occurred, but whether any unexpired Orange Book-listed patent presently prevents generic approval or launch. The mature generic market indicates that no effective blocking patent remains in the United States.
What formulations are protected by aspirin-dipyridamole patents?
The formulation distinction is central to the product’s patent and commercial history.
Immediate-release versus extended-release dipyridamole
Aspirin-dipyridamole is not simply a physical mixture of two inexpensive tablets. Aggrenox uses:
- Aspirin 25 mg.
- Extended-release dipyridamole 200 mg.
- A capsule dosage form.
- Twice-daily administration.
- Modified-release dipyridamole pellets or equivalent controlled-release technology.
The original formulation patents sought to protect the combination’s release characteristics and pharmaceutical composition. Generic manufacturers had to demonstrate bioequivalence to the reference product rather than merely combine commercially available aspirin and immediate-release dipyridamole.
Formulation-related barriers included:
- Release-rate control.
- Pellet or multiparticulate design.
- Capsule filling and uniformity.
- Dissolution performance.
- Stability of the combination.
- Manufacturing consistency at commercial scale.
These barriers delayed simple substitution during the protected period. They do not now support durable pricing power because multiple generic products have demonstrated regulatory feasibility.
How strong is the current patent estate for aspirin-dipyridamole?
The current U.S. patent estate is weak from a commercial defense perspective.
| Factor |
Assessment |
| Active-ingredient exclusivity |
None of practical importance |
| Core combination protection |
Expired or commercially ineffective |
| Extended-release protection |
No longer a meaningful market block |
| Method-of-use protection |
Limited practical value |
| Regulatory exclusivity |
Expired |
| Generic substitution |
Established |
| Litigation leverage |
Low |
| New-product lifecycle opportunity |
Limited without a differentiated delivery system |
A new patent covering a narrow manufacturing process or a specific release profile would not automatically restore the historical Aggrenox franchise. To create material value, a new product would need a clinically meaningful advantage, such as improved tolerability, lower dosing frequency, better adherence, or a new indication supported by clinical data.
What is the FDA regulatory status of aspirin-dipyridamole?
The reference product was approved through a new drug application. Generic products are generally approved through ANDAs demonstrating pharmaceutical equivalence and bioequivalence to the reference drug.
The key regulatory characteristics are:
- Prescription-only status.
- Nonbiologic small-molecule product.
- ANDA pathway for generic entry.
- Therapeutic-equivalence evaluation by FDA.
- No biosimilar pathway.
- No biologic patent dance or reference-product biologic exclusivity.
Does aspirin-dipyridamole face biosimilar risk?
No. Aspirin-dipyridamole is a conventional small-molecule drug, not a biologic. It is subject to generic competition rather than biosimilar competition. The regulatory risk is therefore driven by ANDA approvals, manufacturing quality, supply reliability, and price competition.
What is the financial trajectory of aspirin-dipyridamole?
The financial trajectory has four stages:
- Launch and adoption: Aggrenox established a branded combination for secondary stroke prevention.
- Growth and clinical consolidation: Prescriber familiarity and guideline inclusion supported recurring demand.
- Patent and generic erosion: Generic entry reduced net price and branded volume.
- Mature generic phase: Revenue shifted from a branded franchise to fragmented, lower-margin supply.
Boehringer Ingelheim does not generally disclose Aggrenox as a standalone revenue line in its public financial reporting. As a private company, it provides less granular product-level disclosure than a listed pharmaceutical company. Public filings and corporate reporting therefore do not support a reliable current annual revenue figure for the product.
Revenue exposure
| Revenue driver |
Historical impact |
Current impact |
| Brand price premium |
High |
Minimal |
| Prescription volume |
Positive |
Stable but fragmented |
| Generic substitution |
Low before entry |
Primary market force |
| Reimbursement pressure |
Moderate |
High |
| Clinical guideline support |
Positive |
Maintains baseline demand |
| Competition from clopidogrel |
Negative |
Strong |
| Supply disruptions |
Limited historically |
Can create temporary share shifts |
| Product differentiation |
Moderate |
Minimal |
The product still generates industry revenue through generic volume, but the economics are structurally weaker. Generic prices are shaped by the number of suppliers, payer contracts, wholesaler purchasing, manufacturing costs, and periodic shortages. Revenue can rise temporarily when competitors exit or encounter supply constraints, but such increases are not equivalent to durable franchise growth.
How does aspirin-dipyridamole compare with clopidogrel?
Clopidogrel is the primary commercial comparator because it is inexpensive, widely available, generally administered once daily, and familiar to physicians.
| Attribute |
Aspirin-dipyridamole |
Clopidogrel |
| Active therapy |
Aspirin plus extended-release dipyridamole |
P2Y12 inhibitor |
| Typical secondary stroke-prevention use |
Noncardioembolic stroke or TIA |
Noncardioembolic stroke or TIA |
| Dosing |
Twice daily |
Once daily |
| Generic availability |
Yes |
Yes |
| Headache burden |
Relatively important |
Generally lower |
| Bleeding concern |
Present |
Present |
| Adherence profile |
More complex |
Simpler |
| Commercial pricing |
Low after generic entry |
Low |
| Market differentiation |
Limited |
Stronger convenience profile |
Clopidogrel’s once-daily dosing and broad use in cardiovascular disease give it stronger formulary and prescribing momentum. Aspirin-dipyridamole retains a role for patients who are appropriate candidates and tolerate the regimen, but it lacks a clear economic advantage over generic clopidogrel.
What generic entry risks exist?
Generic entry risk is no longer a future event for aspirin-dipyridamole in the United States. It is the established market structure.
The principal risks are:
- Continued price compression.
- Reduced manufacturing margins.
- Loss of pharmacy shelf preference.
- Contract concentration among large buyers.
- Product discontinuations by smaller suppliers.
- Temporary shortages caused by limited manufacturing capacity.
- Substitution toward clopidogrel or aspirin.
- Reimbursement restrictions.
- Patient discontinuation caused by headache or twice-daily dosing.
Generic suppliers may still earn attractive returns during periods of constrained competition. Those returns depend on supply discipline rather than patent protection.
What manufacturing and intellectual-property barriers remain?
The technical manufacturing barrier is higher than the chemical barrier. Aspirin and dipyridamole are well-known compounds, but a compliant extended-release combination requires control over:
- Modified-release excipients.
- Pellet coating or matrix formation.
- Dissolution testing.
- Capsule content uniformity.
- Stability and moisture control.
- Scale-up reproducibility.
- FDA cGMP compliance.
These requirements can limit the number of reliable suppliers. They do not create the same strategic value as an active patent because competitors can reproduce the product after demonstrating bioequivalence and maintaining compliant manufacturing.
The strongest remaining commercial barrier is operational execution, not intellectual property.
What litigation and settlement agreements affect the product?
The material litigation period was linked to historical generic challenges and patent enforcement. Once generic products entered and the relevant patents expired, the basis for continuing high-value patent litigation diminished.
A current investment or licensing assessment should focus on:
- Whether any ANDA holder faces an FDA compliance action.
- Whether a supplier has discontinued the product.
- Whether a shortage creates temporary pricing power.
- Whether any product-specific recall affects substitution.
- Whether private litigation involves distribution or reimbursement rather than patents.
No active litigation is central to the current commercial thesis based on the mature generic status of the product. Historical settlement terms, if any, would have mattered primarily for the timing of generic launch rather than current market exclusivity.
What is the competitive landscape for aspirin-dipyridamole?
The market is divided between the original brand, generic aspirin/extended-release dipyridamole, and clinically interchangeable antiplatelet alternatives.
Primary competitors
- Generic clopidogrel.
- Generic aspirin.
- Generic aspirin plus short-term clopidogrel in selected acute settings.
- Other antiplatelet products used for specialized cardiovascular indications.
The combination’s demand is supported by guideline recognition and clinician familiarity. Its demand is limited by tolerability, dosing frequency, generic competition, and a lack of commercial differentiation.
What generic launch scenarios are plausible?
The most likely U.S. scenarios are:
| Scenario |
Market outcome |
| Several stable generic suppliers |
Continued price erosion and predictable availability |
| Supplier consolidation |
Lower unit prices but greater shortage risk |
| Manufacturing interruption |
Temporary price increases and share shifts |
| Brand withdrawal or limited distribution |
Generic market becomes the practical standard |
| New differentiated formulation |
Limited opportunity unless supported by clinical benefit |
| Guideline change favoring another therapy |
Further volume decline |
A branded relaunch would require more than patent protection. It would need a reimbursement-supported clinical proposition, such as improved adherence or reduced adverse events.
What is the geographic coverage of aspirin-dipyridamole?
The product has had broad international exposure, but brand names, regulatory status, reimbursement, and generic availability vary by jurisdiction.
| Region |
Market profile |
| United States |
Mature generic market; Aggrenox is primarily a historical brand reference |
| European Union |
Combination products have been marketed under country-specific names and reimbursement rules |
| United Kingdom |
Use is influenced by National Institute for Health and Care Excellence guidance and National Health Service prescribing economics |
| Canada |
Generic substitution and provincial reimbursement shape access |
| Emerging markets |
Availability depends on local registration, manufacturing, and procurement |
Geographic commercial value is therefore jurisdiction-specific. Expired U.S. patents do not determine freedom to operate in every country, although the underlying actives and principal formulation concepts are old across most major markets.
Key Takeaways
- Aspirin-dipyridamole is an established secondary stroke-prevention combination marketed in the United States as Aggrenox.
- FDA approved Aggrenox in 1999.
- The product’s commercial exclusivity ended after mid-2010s generic entry and the expiration of core formulation-related protection.
- Current value is concentrated in generic volume rather than branded pricing.
- The product has no biosimilar risk because it is a small-molecule drug.
- Clopidogrel is the strongest commercial substitute because of once-daily dosing, broad use, and low generic cost.
- Remaining barriers are manufacturing quality, bioequivalence, supply reliability, and contracting rather than patents.
- Boehringer Ingelheim does not publicly provide a reliable standalone current revenue figure for Aggrenox.
- The commercial outlook is stable but low growth, with temporary upside possible during generic supply disruptions.
- A viable lifecycle-management strategy would require a differentiated formulation or clinically validated adherence and tolerability advantage.
FAQs
Is Aggrenox still commercially available?
Aggrenox has largely been displaced by generic aspirin and extended-release dipyridamole capsules in the United States. Availability of the original brand can vary by distributor and pharmacy.
Is aspirin-dipyridamole more effective than clopidogrel?
Clinical evidence does not establish a broad superiority advantage. The PRoFESS trial found broadly comparable recurrent-stroke outcomes, with different bleeding and tolerability profiles [2].
Why is aspirin-dipyridole prescribed twice daily?
The extended-release dipyridamole component is administered twice daily to maintain exposure and deliver the labeled formulation profile.
Can a new company patent a reformulated aspirin-dipyridamole product?
Potentially, but a commercially meaningful patent would need to cover a novel, non-obvious formulation or delivery system. A narrow manufacturing claim alone would be unlikely to recreate the historical brand economics.
What would increase the value of an aspirin-dipyridamole franchise?
The strongest value drivers would be a clinically demonstrated reduction in headache or bleeding, once-daily dosing, improved adherence, reliable global supply, or a new indication supported by regulatory-quality evidence.
References
-
U.S. Food and Drug Administration. (1999). Aggrenox prescribing information. FDA.
-
Sacco, R. L., Diener, H.-C., Yusuf, S., Cotton, D., Ounpuu, S., Lawton, W. A., Palesch, Y., Martin, R. H., Albers, G. W., Bath, P., Bornstein, N., Chan, B. P. L., Chen, S.-T., Cunha, L., Dahlöf, B., De Keyser, J., Donnan, G. A., Estol, C., Gorelick, P., ... PRoFESS Study Group. (2008). Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. New England Journal of Medicine, 359(12), 1238-1251. https://doi.org/10.1056/NEJMoa0805002
-
Kleindorfer, D. O., Towfighi, A., Chaturvedi, S., Cockroft, K. M., Gutierrez, J., Lombardi-Hill, D., Kamel, H., Kernan, W. N., Kittner, S. J., Leira, E. C., Lennon, O., Meschia, J. F., Nguyen, T. N., Pollak, P. M., Santangeli, P., Sharrief, A. Z., Smith, E. E., & Williams, L. S. (2021). 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke, 52(7), e364-e467. https://doi.org/10.1161/STR.0000000000000375
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/
